Acute myelogenous leukemia stem cells: from Bench to Bedside

Area of Science:

• Hematology
• Cancer Biology
• Translational Research

Background:

• Adult acute myeloid leukemia (AML) patients often relapse despite achieving remission with standard chemotherapy.
• A rare subpopulation of leukemia cells, known as leukemia stem cells (LSCs), are resistant to conventional treatments and drive disease recurrence.
• LSCs possess self-renewal capabilities and are responsible for initiating and maintaining the leukemia.

Purpose of the Study:

• To review current translational research on leukemia stem cells (LSCs) in acute myeloid leukemia (AML).
• To focus on novel strategies for detecting LSC burden and understanding their prognostic significance.
• To highlight the identification and development of therapeutic agents specifically targeting LSCs.

Main Methods:

• Review of existing translational research literature on LSCs in AML.
• Discussion of emerging techniques for quantifying LSC populations.
• Analysis of studies investigating the clinical implications of LSC burden.
• Overview of therapeutic strategies aimed at eradicating LSCs.

Main Results:

• Leukemia stem cells (LSCs) are a critical factor in AML relapse and treatment resistance.
• New methods are being developed to accurately detect and quantify LSC burden.
• LSC burden has significant prognostic implications for AML patients.
• Targeting LSCs represents a promising therapeutic avenue for improving patient outcomes.

Conclusions:

• Leukemia stem cells (LSCs) are central to AML relapse and mortality.
• Accurate detection and prognostic assessment of LSC burden are crucial for personalized treatment strategies.
• Developing therapies specifically targeting LSCs is essential for overcoming treatment resistance and improving survival in AML.